GLP-1 Research: What the Current Evidence Shows

• GLP-1 agonists are a class of medications that mainly help with blood sugar control, and some are also used for obesity.
• In one large trial described in the research, semaglutide lowered the risk of heart attack, stroke, or cardiovascular death by 20% in people with heart disease who did not have diabetes.
• Weight loss is not the only issue. The research also points to hair thinning, muscle loss concerns, and the need for a maintenance plan after goal weight is reached.
• Newer drugs in this space, including tirzepatide and retatrutide, are being compared by their trial results, but they are not the same drug and do not have the same evidence base.

What GLP-1 Is

GLP-1 stands for glucagon-like peptide-1. It is a hormone made by the small intestine. In the body, it helps trigger insulin release, which lowers blood sugar. That is why GLP-1-based drugs were first used in type 2 diabetes care. Cleveland Clinic notes that GLP-1 agonists are a class of medications that mainly help manage blood sugar, and that some are also used to treat obesity.

These medications are often injectable and are given under the skin. Cleveland Clinic also notes that the first GLP-1 agonist approved by the FDA was exenatide in 2005. That matters because the class is still relatively new, and researchers are still learning about its full range of effects.

For readers comparing the broader peptide space, GLP-1 is often discussed alongside Semaglutide and Tirzepatide, which are part of the same modern weight-loss and metabolic conversation. Newer agents such as Retatrutide are also drawing attention because of early trial data.

What The Research Shows

Weight loss is real, but it is not the whole story

The supplied research repeatedly frames GLP-1 drugs through weight loss, and that is not wrong. One source describes semaglutide clinical trials showing an average body weight reduction of around 15%. Another source contrasts that with tirzepatide at about 21% and retatrutide at 28.7% in a phase 3 trial at 68 weeks.

That 28.7% figure is striking, but it should be read in context. It comes from a YouTube discussion of phase 3 data, not from a full paper in the bundle. The takeaway is narrower and safer: newer incretin-based drugs may produce larger average weight loss than earlier GLP-1 drugs, but the drugs are not interchangeable, and the evidence base is not identical.

Cardiovascular findings changed the discussion

One of the clearest findings in the research comes from the SELECT trial as described in the source material. In that study, more than 17,000 people with heart disease and overweight or obesity, but without diabetes, were randomized to semaglutide or placebo. The reported result was a 20% reduction in the risk of heart attack, stroke, or death from a heart-related event.

The source also says the benefit appeared early, faster than would be expected if it were caused only by weight loss. That is an important point for clinicians and researchers. It suggests GLP-1 drugs may do more than reduce body weight, at least in some settings.

That does not mean every GLP-1 drug has the same cardiovascular data. It means one well-described semaglutide trial showed a major heart benefit in a high-risk population without diabetes.

Side effects matter

The research also highlights side effects that patients may not expect. One news report in the bundle describes temporary hair thinning linked to GLP-1 drugs such as Ozempic, Wegovy, and Zepbound. The report says the effect may be more common in women than men, and that rapid weight loss can play a role.

The same report says the hair shedding is temporary and that steady weight loss and healthy eating may help. A salon owner quoted in the report said hair thinning can start within 2 to 3 months after the first injection. That is not proof of a universal timeline, but it does show the kind of delayed effect patients may notice.

Another source in the bundle, an Instagram reel, claims these drugs cause osteoporosis, depression, apathy, and loss of joy. Those statements are not supported elsewhere in the provided research, so they should not be treated as established conclusions here.

Dose, Maintenance, And Long-Term Use

One GoodRx source in the bundle says a GLP-1 maintenance dose is recommended after reaching goal weight. It also says the dose may be lowered or the dosing interval may be adjusted, depending on the person and the medication. The practical point is simple: reaching a target weight is not always the end of treatment planning.

This is important because GLP-1 use is often discussed as if the only milestone is the scale. The research suggests a second phase matters just as much. People may need a lower ongoing dose or another maintenance plan to help prevent regain and support healthier long-term results.

That maintenance question also matters for researchers. A drug that works during active weight loss may still need a different strategy once the patient stabilizes. The bundle gives no single universal maintenance protocol, which is consistent with the idea that this is individualized.

Muscle, Hair, And Other Practical Questions

One of the stronger themes in the video material is that muscle loss should not be ignored. The presenter in one source says this question is especially important for people in their 50s or 60s, but it also matters for younger adults. The reason is clear: rapid weight loss can change more than fat mass.

The bundle does not give a full body-composition dataset, so it would be wrong to claim a precise amount of muscle loss from these sources alone. Still, the concern itself is supported. If weight falls quickly, patients and clinicians should think about nutrition, resistance training, and whether the loss is coming from the right places.

Hair thinning fits the same pattern. It is not the main purpose of GLP-1 therapy, but it can become part of the patient experience. In the supplied research, the message is that some of these changes may be temporary, but they still affect adherence and satisfaction.

How To Read Comparisons Between GLP-1 Drugs

It is tempting to rank every drug in this space as if there were one scoreboard. The research does not support that kind of simplification. Semaglutide has specific cardiovascular evidence in the SELECT trial. Tirzepatide is discussed as more effective for weight loss than semaglutide in some comparisons. Retatrutide is described as even more potent in early phase 3 data.

But “stronger” does not automatically mean “better” for every person. What matters depends on the goal. For a researcher, the question may be efficacy, mechanism, or safety. For a clinician, the question may be glycemic control, weight reduction, or cardiovascular risk. For a biohacker, the question may be how to preserve lean mass and tolerate the drug over time.

The research also shows how fast this area is moving. Some sources are discussing oral GLP-1 pills, while others focus on newer injectable agents. That means comparisons should be made carefully, with attention to the exact trial, the exact dose, and the exact endpoint.

What This Means In Practice

The safest conclusion from the supplied material is this: GLP-1 drugs have moved well beyond blood sugar control. They are now being studied and used in obesity, cardiovascular risk reduction, and long-term weight management. The evidence in the bundle supports benefits, but it also supports caution.

Caution means recognizing side effects. It means thinking about muscle and hair, not just pounds lost. It means planning for maintenance after target weight is reached. And it means not assuming that every new drug in the incretin class has the same data or the same role.

For anyone reading the literature, the most useful habit is to ask three questions. What was the population? What was the endpoint? And how long was the follow-up? Those details separate a headline from a usable result.

FAQ

What does GLP-1 do in the body?

GLP-1 is a hormone made by the small intestine. It helps trigger insulin release from the pancreas, which lowers blood sugar. That is the basic biological reason GLP-1-based drugs can help with diabetes care.

Are GLP-1 agonists only for diabetes?

No. The research says some GLP-1 agonists are also used to treat obesity. The bundle also includes evidence from a semaglutide heart trial in people without diabetes, showing that the class is being studied for more than glucose control alone.

How much weight loss do these drugs produce?

In the provided research, semaglutide is described as producing about 15% average body weight reduction in trial data. Tirzepatide is described at about 21%, and retatrutide at 28.7% in a phase 3 trial at 68 weeks. These numbers come from different sources in the bundle and should not be treated as direct head-to-head trial results unless a study specifically compares them.

Do GLP-1 drugs affect the heart?

Yes, at least semaglutide did in the SELECT trial described in the research. That study reported a 20% reduction in the risk of heart attack, stroke, or cardiovascular death in people with heart disease and overweight or obesity who did not have diabetes.

What side effects should people watch for?

The supplied research points to temporary hair thinning and the need to think carefully about muscle loss during rapid weight reduction. It also says maintenance dosing may be needed after goal weight is reached. Other claims, such as osteoporosis, depression, or apathy, are not established by the material provided here.